A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-06-12
Target enrollment:
Participant gender:
Summary
This is a Phase 1 open label study to evaluate the tolerability, safety, immunogenicity, and
efficacy of SW1115C3, a neoantigen mRNA personalised cancer vaccine，in patients with advanced
malignant solid tumours.